



Sun Pharma Switzerland LTD  
Indian Format Financial Statements  
FY 2016 – 2017  
1 April 2016 – 31 March 2017

<b>VALIA &amp; TIMBADIA</b> <b>CHARTERED ACCOUNTANTS</b>	Tel: Off: 2269 2624 / 2269 9664/40040216 E-mail: <a href="mailto:valtim09@gmail.com">valtim09@gmail.com</a> 32, Trinity Chambers, 117, Bora Bazar Street, Fort, Mumbai – 400 001.
<b>ARVIND P. VALIA</b> B.COM. (Hons.), F.C.A. <b>HITEN C. TIMBADIA</b> B.COM. L.L.B. (GEN), F.C.A.	

## INDEPENDENT AUDITOR'S REPORT

**TO THE MEMBERS OF SUN PHARMA SWITZERLAND LTD.**

### Report on the Financial Statements

We have audited the accompanying Ind AS Financial Statements of **SUN PHARMA SWITZERLAND LTD.** (the "Company"), which comprise the Balance Sheet as at March 31, 2017 and the Statement of Profit and Loss (including other Comprehensive income), the statement of Cash Flows and Statement of Changes in Equity for the year then ended, and a summary of significant accounting policies and other explanatory information.

### Management's Responsibility for the Financial Statements

The Management of the Company is responsible for the preparation of these financial statements that give a true and fair view of the financial position and financial performance of the Company in accordance with the Accounting Standards and Accounting Principles generally accepted in India. The responsibility includes the design, implementation and maintenance of adequate internal financial controls, that are operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

### Auditors' Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Company's preparation and fair presentation of the financial statements, in order to design audit procedures that are appropriate in the circumstances. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of the accounting estimates made by the Management of the Company, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion these financial statements.

**VALIA & TIMBADIA**  
CHARTERED ACCOUNTANTS

**ARVIND P. VALIA**  
B.COM. (Hons.), F.C.A.  
**HITEN C. TIMBADIA**  
B.COM. L.L.B. (GEN), F.C.A.

Tel: Off: 2269 2624 / 2269 9664/40040216  
E-mail: [valtim09@gmail.com](mailto:valtim09@gmail.com)  
32, Trinity Chambers,  
117, Bora Bazar Street, Fort,  
Mumbai – 400 001.

**Opinion**

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India of the financial position of the Company as at 31 March, 2017, and its financial performance including other comprehensive income, its cash flows and the changes in equity for the year ended on that date.

FOR **VALIA AND TIMBADIA**  
CHARTERED ACCOUNTANTS  
(Firm Registration No. 112241W)

**HITEN C. TIMBADIA**  
Partner  
Membership No. 038429.

PLACE: MUMBAI  
DATED: 10<sup>TH</sup> May, 2017



**SUN PHARMA SWITZERLAND LTD.**  
**BALANCE SHEET AS AT MARCH 31, 2017**

in CHF

	Notes	As at 31-mrt-17	As at 31-mrt-16	As at 1-apr-15
<b>ASSETS</b>				
<b>Non-current assets</b>				
Investments in subsidiaries	1	40.558.749	-	-
Total non-current assets		40.558.749	-	-
<b>Current assets</b>				
Financial assets				
Trade receivables	2	115.111	-	-
Cash and cash equivalents	3	38.733	81.006	88.825
Other current assets	4	100.166	1.315	1.215
Total current assets		254.010	82.321	90.040
<b>TOTAL ASSETS</b>		<b>40.812.759</b>	<b>82.321</b>	<b>90.040</b>
<b>EQUITY AND LIABILITIES</b>				
<b>Equity</b>				
Equity share capital	5	100.000	100.000	100.000
Other equity		(436.985)	(21.589)	(14.582)
Total equity		(336.985)	78.411	85.418
<b>Current liabilities</b>				
Financial liabilities				
Borrowings	6	41.097.146	-	-
Trade payables	7	34.332	3.910	4.622
Other current liabilities	8	18.266	-	-
Total current liabilities		41.149.744	3.910	4.622
<b>TOTAL EQUITY AND LIABILITIES</b>		<b>40.812.759</b>	<b>82.321</b>	<b>90.040</b>
		-	-	-

See accompanying notes to the financial statements

In terms of our report of even date attached

**For Valia & Timbadia**  
Chartered Accountants

**For and on behalf of the Board**

**Hiten C Timbadia**  
Partner

**Prashant Savla**  
Director

Date: 10th of may 2017

Date: 8th of may 2017

Place: Mumbai, India

Place: Hoofddorp, The Netherlands

**SUN PHARMA SWITZERLAND LTD.**  
**STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED MARCH 31, 2017**

in CHF

	Notes	Year ended 31-mrt-17	Year ended 31-mrt-16
Other income	9	16.297	-
<b>Total income</b>		16.297	-
<b>Expenses</b>			
Finance costs	10	836	-
Other expenses	11	418.204	7.007
<b>Total expenses</b>		419.040	7.007
<b>Loss before exceptionals item and tax</b>		(402.743)	(7.007)
Exceptional items			
<b>Loss before tax</b>		(402.743)	(7.007)
<b>Tax expenses</b>			
Current tax	12	12.653	
<b>Loss for the year</b>		(415.396)	(7.007)
<b>Total comprehensive loss for the year</b>		<b>(415.396)</b>	<b>(7.007)</b>
<b>Earnings per equity share (face value per equity shares - ` 1)</b>		(4.153,96)	(70,07)
Basic (in `)			
Diluted (in `)			
See accompanying notes to the financial statements			
In terms of our report of even date attached <b>For Valia &amp; Timbadia</b> <i>Chartered Accountants</i>		<b>For and on behalf of the Board</b>	
<b>Hiten C Timbadia</b> Partner		<b>Prashant Savla</b> <i>Director</i>	
Date: 10th of may 2017		Date: 8th of may 2017	
Place: Mumbai, India		Place: Hoofddorp, The Netherlands	

SUN PHARMA SWITZERLAND LTD.  
STATEMENT OF CHANGES OF EQUITY FOR THE YEAR ENDED MARCH 31, 2017

	Share application money pending allotment	Share suspense account	Capital reserve	Securities premium reserve	Debtenture redemption reserve	Share option outstanding account	Reserve and surplus			Retained earnings (Surplus in profit and loss)	Other comprehensive income (OCI)		Total
							Amalgamation reserve	Capital redemption reserve	General reserve		Equity instrument through OCI	Effective portion of cash flow hedge	
<b>Balance as at April 1, 2015</b>										(14,582.0)		(14,582.0)	
Loss for the year										(7,007.0)		(7,007.0)	
Other comprehensive income for the year, net of income tax													
<b>Total comprehensive income for the year</b>										(7,007.0)		(7,007.0)	
Payment of dividend													
Corporate dividend tax													
Scheme of amalgamation													
Transfer of capital redemption reserve													
Transfer of debtenture redemption reserve													
Issue of share capital													
Buy-back of equity shares													
Exercise of share option													
Transfer to General Reserve													
Share-based payments (amortisation)													
<b>Balance as at March 31, 2016</b>										(21,589.0)		(21,589.0)	
Loss for the year													
Other comprehensive income for the year, net of income tax										(415,396.0)		(415,396.0)	
<b>Total comprehensive income for the year</b>										(415,396.0)		(415,396.0)	
Payment of dividend													
Corporate dividend tax													
Transfer to revaluation													
Transfer of capital redemption reserve													
Issue of share capital													
Buy-back of equity shares													
Exercise of share option													
Transfer to General Reserve													
Share-based payments (amortisation)													
<b>Balance as at March 31, 2017</b>										(436,985.0)		(436,985.0)	

In terms of our report of even date attached  
For Valia & Timbadia  
Chartered Accountants

For and on behalf of the Board

Hiten C Timbadia  
Partner

Prashant Savia  
Director

Date: 10th of may 2017

Date: 8th of may 2017

Place: Mumbai, India

Place: Hoofddorp, The Netherlands

in CHF



**SUN PHARMA SWITZERLAND LTD.**  
**CASH FLOW STATEMENT FOR THE YEAR ENDED 31ST MARCH, 2017**

PARTICULARS	FOR THE YEAR ENDED 31.03.2017 Amount in CHF		FOR THE YEAR ENDED 31.03.2016 Amount in CHF	
<b>A) Cash flow From Operating Activities</b>				
Net Profit Before Tax		(415.396)		(7.007)
<u>Adjustments for</u>				
Profit on sale of Investment				
Other Income (Interest and investment income)				
Interest Expenses				
Depreciation/Amortization/Impairment of Fixed Assets		-		-
<b>Operating (Loss) / Profit before Working Capital change</b>				
<b>Changes in working capital</b>				
<i>Adjustments for (increase) / decrease in operating assets:</i>				
Decrease / (Increase) in Inventory		-		-
Decrease / (Increase) in Sundry Debtors	(115.111)			-
Decrease / (Increase) in Loans and Advances				
<i>Adjustments for increase / (decrease) in operating liabilities:</i>				
(Decrease) / Increase - Trade & Other payables	(50.163)		(812)	
Income Tax paid				
<b>Net Cash Flows from Operating Activities</b>		(165.274)		(812)
<b>B) Cash Flow from Investing Activities</b>				
Decrease / (Increase) in Non-Current Investments	(40.558.749)			
Decrease / (Increase) in Current Investments		-		
Interest and investment income				
Decrease / (Increase) in Other Receivables				
Other Non-Operating Income				
<b>Net Cash Flows from Investing Activities</b>		(40.558.749)		-
<b>C) Cash Flow from Financing Activities</b>				
Decrease / (Increase) in Loans and Advances				
Proceeds from issue of Equity Shares				
Interest Income				
Increase / (Decrease) in Long Term Borrowings				
Interest Expenses				
Increase / (Decrease) in Short Term Borrowings	41.097.146			
<b>Net Cash Flows from Financing Activities</b>		41.097.146		-
<b>Net Increase / (Decrease) in Cash &amp; Cash equivalents</b>		(42.273)		(7.819)
Cash & Cash Equivalents at Beginning of the year	81.006		88.825	
<b>Cash &amp; Cash Equivalents at the End of the Year</b>	38.733		81.006	

Note : Cash & Cash Equivalents Consist of the cash /cheque in hand & bank balance in current Account.

In terms of our report of even date attached  
**For Valia & Timbadia**  
Chartered Accountants

For and on behalf of the Board

**Hiten C Timbadia**  
Partner

**Prashant Savla**  
Director

Date: 10th of may 2017

Date: 8th of may 2017

Place: Mumbai, India

Place: Hoofddorp, The Netherlands

SUN PHARMA SWITZERLAND LTD.  
 NOTES FORMING PART OF FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2017

NOTE : 1

INVESTMENTS IN SUBSIDIARIES

in CHF

	As at 31-mrt-17		As at 31-mrt-16		As at 1-apr-15	
	Qty.		Qty.		Qty.	
Un-quoted - equity shares (At cost) Ocular Technologies SARL Shares of 100 CHF each fully paid	200	40.558.749				
		40.558.749		-		-



SUN PHARMA SWITZERLAND LTD.  
NOTES FORMING PART OF FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2017

NOTE : 2  
TRADE RECEIVABLES

	As at 31-mrt-17	As at 31-mrt-16	As at 1-apr-15
<b>Current</b>			
Unsecured considered good - from related parties	115.111	-	-
	115.111	-	-

NOTE : 3  
CASH AND CASH EQUIVALENTS

	As at 31-mrt-17	As at 31-mrt-16	As at 1-apr-15
Balances with banks In current accounts	38.733	81.006	88.825
	38.733	81.006	88.825

NOTE : 4  
OTHER CURRENT ASSETS

	As at 31-mrt-17	As at 31-mrt-16	As at 1-apr-15
<b>Unsecured considered good unless stated otherwise</b>			
Prepaid expenses	77.761	1.255	1.215
Balances with government authorities	22.405	60	
	100.166	1.315	1.215

NOTE : 5  
EQUITY SHARE CAPITAL

	As at 31-mrt-17		As at 31-mrt-16		As at 1-apr-15	
	No. of shares	in CHF	No. of shares	in CHF	No. of shares	in CHF
<b>Authorised</b>						
Equity shares of ` 1 each						
Cumulative preference shares of ` 100 each						
	0	-	0	-	0	-
<b>Issued, subscribed and fully paid up</b>						
Equity Shares of ` 1 each	100	100.000	100	100.000	100	100.000
	100	100.000	100	100.000	100	100.000
<b>Reconciliation of fully paid equity shares</b>						
Opening balance	100,00	100.000	100,00	100.000		
Add : shares allotted during the year pursuant to the scheme of amalgamation						
Add : shares allotted to employees on exercise of employee stock option (excluding shares held by ESOP trust)						
Less : buy back of shares						
Closing balance	100,00	100.000	100,00	100.000		
<b>Details of shareholders holding more than 5% in the Company</b>						
<b>Equity shares</b>						
Alkaloida Chemical Company	100	100	100	100	100	100

SUN PHARMA SWITZERLAND LTD.  
NOTES FORMING PART OF FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2017

NOTE : 6

SHORT TERM BORROWINGS

	As at 31-mrt-17	As at 31-mrt-16	As at 1-apr-15
Unsecured Inter-corporate deposits From related parties	41.097.146		
	41.097.146	-	-

NOTE : 7

TRADE PAYABLES

	As at 31-mrt-17	As at 31-mrt-16	As at 1-apr-15
Others	34.332	3.910	4.622
	34.332	3.910	4.622

NOTE : 8

OTHER CURRENT LIABILITIES

	As at 31-mrt-17	As at 31-mrt-16	As at 1-apr-15
Statutory remittances	5.866		
Others	12.400		
	18.266	-	-

NOTE : 9

OTHER INCOME

	Year ended 31-mrt-17	Year ended 31-mrt-16
Other non-operating income (net of expenses directly attributable to such income) Miscellaneous income	16.297	
	16.297	-

NOTE : 10

FINANCE COSTS

	Year ended 31-mrt-17	Year ended 31-mrt-16
Interest expense on borrowing and others	836	
	836	-

NOTE : 11

OTHER EXPENSES

	Year ended 31-mrt-17	Year ended 31-mrt-16
Rent	1.643	
Professional, legal and consultancy	17.753	5.329
Net (gain) / loss on foreign currency transactions and translation	395.878	
Payments to auditors (net of input credit, where applicable) As auditors	1.031	430
Miscellaneous expenses	1.899	1.248
	418.204	7.007

SUN PHARMA SWITZERLAND LTD.  
 NOTES FORMING PART OF FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2017

NOTE : 12

TAX RECONCILIATION

in CHF

	Year ended 31-mrt-17	Year ended 31-mrt-16
<b>Reconciliation of current tax expense</b>		
Profit before tax	(402.743)	(7.007)
Enacted income tax rate (%)		
Tax expense	12.653	-
	12.653	-
Income tax expense recognised in profit and loss	12.653	-

**SUN PHARMA SWITZERLAND LTD.**  
**NOTES FORMING PART OF FINANCIAL STATEMENTS AS AT AND FOR YEAR ENDED MARCH 31, 2017**

**NOTE : 13**

**(A) ACCOUNTING POLICIES :**

**1. Basis of Accounting**

The Company has prepared financial statements for the year ended March 31, 2017 in accordance with Indian Accounting Standards (Ind AS) notified under the Companies (Indian Accounting Standards) Rules, 2015 together with the comparative period data as at and for the year ended March 31, 2016. Further, the Company has prepared the opening balance sheet as at April 1, 2015 (the transition date) in accordance with Ind AS.

Upto the year ended March 31, 2016, the company prepared its financial statements in accordance with the requirements of previous GAAP, which includes Standards notified under the Companies (Accounting Standards) Rules, 2006 (as amended).

The financial statements have been prepared on the historical cost basis, except for certain financial instruments that are measured at fair values at the end of each reporting period, as explained in the accounting policies below.

Historical cost is generally based on the fair value of the consideration given in exchange for goods, services, etc. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, regardless of whether that price is directly observable or estimated using another valuation technique.

**2. Financial Assets**

**i. Initial recognition and measurement**

All financial assets are recognised initially at fair value plus, in the case of financial assets not recorded at fair value through profit or loss, transaction costs that are attributable to the acquisition of the financial asset. Purchases or sales of financial assets that require delivery of assets within a time frame established by regulation or convention in the market place (regular way trades) are recognised on the trade date.

**ii. Subsequent measurement**

For purposes of subsequent measurement, financial assets are classified in four categories:

- Debt instruments at amortised cost
- Debt instruments at fair value through other comprehensive income (FVTOCI)
- Debt instruments and equity instruments at fair value through profit or loss (FVTPL)
- Equity instruments measured at fair value through other comprehensive income (FVTOCI)

**iii. Debt instruments at amortised cost**

A 'debt instrument' is measured at the amortised cost if both the following conditions are met:

- a) The asset is held within a business model whose objective is to hold assets for collecting contractual cash flows, and
- b) Contractual terms of the asset give rise on specified dates to cash flows that are solely payments of principal and interest (SPPI) on the principal amount outstanding

This category is the most relevant to the Group. After initial measurement, such financial assets are subsequently measured at amortised cost using the effective interest rate (EIR) method. Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortisation is included in Other Income in the profit or loss. The losses arising from impairment are recognised in the profit or loss.

**iv. Debt instrument at FVTPL**

FVTPL is a residual category for debt instruments. Any debt instrument, which does not meet the criteria for categorization as at amortized cost or as FVTOCI, is classified as at FVTPL.

In addition, the group may elect to designate a debt instrument, which otherwise meets amortized cost or FVTOCI criteria, as at FVTPL. However, such election is allowed only if doing so reduces or eliminates a measurement or recognition inconsistency (referred to as 'accounting mismatch'). The group has not designated any debt instrument as at FVTPL.

Debt instruments included within the FVTPL category are measured at fair value with all changes recognized in the profit or loss

**v. Equity instruments**

Equity instruments included within the FVTPL category are measured at fair value with all changes recognized in the profit or loss



### 3. Financial liabilities and equity instruments

#### Classification as debt or equity

Debt and equity instruments issued by a group entity are classified as either financial liabilities or as equity in accordance with the substance of the contractual arrangements and the definitions of a financial liability and an equity instrument

#### a. Equity Instruments

An equity instrument is any contract that evidences a residual interest in the assets of an entity after deducting all of its liabilities. Equity instruments issued by a group entity are recognised at the proceeds received, net of direct issue costs.

#### b. Compound financial instruments

The component parts of compound financial instruments (convertible notes) issued by the Company are classified separately as financial liabilities and equity in accordance with the substance of the contractual arrangements and the definitions of a financial liability and an equity instrument

#### i. Initial recognition and measurement

All financial liabilities are recognised initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs.

#### ii. Subsequent measurement

All financial liabilities are subsequently measured at amortised cost using the effective interest method or at FVTPL.

#### Financial liabilities at fair value through profit or loss

Financial liabilities are classified as at FVTPL when the financial liability is either contingent consideration recognised by the Group as an acquirer in a business combination to which Ind AS 103 applies or is held for trading or is designated upon initial recognition as at fair value through profit or loss. Financial liabilities are classified as held for trading if they are incurred principally for the purpose of repurchasing in the near term or on initial recognition it is part of a portfolio of identified financial instruments that the Group manages together and has a recent actual pattern of short-term profit-taking. This category also includes derivative entered into by the group that are not designated and effective as hedging instruments in hedge relationships as defined by Ind AS 109. Gains or losses on liabilities held for trading are recognised in the profit or loss.

Financial liabilities designated upon initial recognition at fair value through profit or loss are designated as such at the initial date of recognition, and only if the criteria in Ind AS 109 are satisfied. For non-held-for-trading financial liabilities designated as at FVTPL, fair value gains/ losses attributable to changes in own credit risk are recognized in OCI, unless the recognition of the effects of changes in the liability's credit risk in other comprehensive income would create or enlarge an accounting mismatch in profit or loss, in which case these effects of changes in credit risk are recognised in profit or loss. These gains/ loss are not subsequently transferred to profit or loss. All other changes in fair value of such liability are recognised in the statement of profit or loss. The group has not designated any financial liability as at fair value through profit and loss.

#### Financial liabilities subsequently measured at amortised cost

Financial liabilities that are not held-for-trading and are not designated as at FVTPL are measured at amortised cost at the end of subsequent accounting periods. The carrying amounts of financial liabilities that are subsequently measured at amortised cost are determined based on the effective interest method. Interest expense that is not capitalised as part of costs of an asset is included in the 'Finance costs' line item

### 4. Recognition of Revenue

Revenue is measured at the fair value of the consideration received or receivable.

#### a. Rendering Services

Revenue from services rendered is recognized in the profit or loss as the underlying services are performed. Upfront non-refundable payments received are deferred and recognized as revenue over the expected period over which the related services are expected to be performed.

#### b. Interest Income

Interest income from a financial asset is recognised when it is probable that the economic benefits will flow to the Group and the amount of income can be measured reliably. Interest income is accrued on a time basis, by reference to the principal outstanding and at the effective interest rate applicable, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to that asset's net carrying amount on initial recognition.

#### c. Profit from Investments

Profit from Non Current Investments are calculated on the basis of FIFO method.

Profit from Current Investments are calculated on the basis of NAV.

### 5. Risk Management

The Company's activities are not exposed to any material financial risks including market risk, credit risk and liquidity risk.

### 5.a Accounting Standard (AS-20) on Earnings Per Share

	Year ended 31st March, 2017	Year ended 31st March, 2016
Profit for the year - used as Numerator for calculating Earnings Per Share	(415.396)	(7.007)
Weighted Average number of Shares used in computing Basic Earnings Per Share	100	100
Add: Dilution effect of Employee Stock Options	-	-
Weighted Average number of Shares used in computing Diluted Earnings Per Share	100	100
Nominal value per share (in CHF)	100	100
Basic Earnings Per Share (in CHF)	(4.154)	(70)
Diluted Earnings Per Share (in CHF)	(4.154)	(70)

### 5.b Related Party Transactions

	Year ended 31st March, 2017	Year ended 31st March, 2016
<b>Other Income</b>		
Sun Pharma Global (FZE)	16.297	-
<b>Interest Expense</b>		
Alkaloida Chemical Company Zrt.	836	-
<b>Trade Receivables</b>		
Ocular Technologies Ltd.	272	-
Sun Pharma Global (FZE)	114.839	-
<b>Loans Taken</b>		
Alkaloida Chemical Company Zrt.	150.836	-
Ocular Technologies Ltd.	40.946.310	-
<b>Investment</b>		
Ocular Technologies Ltd.	40.558.749	-

### 5.c Significant Transactions during the year

On 15th December 2016 the year Ocular Technologies Ltd. was purchased for the amount of USD 40.500.000. This purchased was financed by SPG FZE with a loan of USD 40.500.000.

As on 31st March 2017, Ocular Technologies has sold their IP to SPG FZE for the amount of USD 40.500.000. It was agreed that, as settlement of the Transfer Price, the loan between SPG FZE and Sun Switzerland shall be transferred to Ocular Technologies.

	USD	USD
Purchase Ocular Technologies - Investment	40.500.000	
Loan SPG FZE		(40.500.000)
*) Ocular Technologies - Sale of IP	40.500.000	
*) Ocular Technologies - Trade Payable SPG FZE		(40.500.000)
Loan SPG FZE transfer to Ocular Technologies	40.500.000	
Loan Ocular Technologies transfer from SPG FZE		(40.500.000)

\*) This is a transfer reflected in the books of Ocular Technologies Ltd.



## 6. Taxes on Income

Income tax expense consists of current and deferred tax. Income tax expense is recognized in profit or loss except to the extent that it relates to items recognized in other comprehensive income or directly in equity, in which case it is recognized in other comprehensive income or directly in equity respectively. Current tax is the expected tax payable on the taxable profit for the year, using tax rates enacted or substantively enacted by the end of the reporting period, and any adjustment to tax payable in respect of previous years.

Deferred tax is recognised on temporary differences between the carrying amounts of assets and liabilities in the consolidated financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax is not recognized for the following temporary differences: the initial recognition of assets or liabilities in a transaction that is not a business combination and that affects neither accounting nor taxable profits and taxable temporary differences arising upon the initial recognition of goodwill

Deferred tax is measured at the tax rates that are expected to be applied to the temporary differences when they reverse, based on the laws that have been enacted or substantively enacted by the end of the reporting period.

A deferred tax asset is recognized to the extent that it is probable that future taxable profits will be available against which the temporary difference can be utilized. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized.

## 7. Provisions, Contingent Liabilities and Contingent Assets

Provisions are recognised only when there is a present obligation as a result of past events and it is probable that an outflow of resources will be required to settle the obligation in respect of which a reliable estimate of the amount of the obligation can be made. Contingent liability is disclosed for (i) Possible obligations which will be confirmed only by future events not wholly within the control of the Company or (ii) Present obligations arising from past events where it is not probable that an outflow of resources will be required to settle the obligation or a reliable estimate of the amount of the obligation cannot be made. Contingent Assets are not recognised in the financial statements.

8 Accounting policies not specifically mentioned above will be as per generally accepted accounting principles in India.

## (B) First-time adoption of Ind-AS

These financial statements for the year ended March 31, 2017 have been prepared in accordance with Ind AS. For the purposes of transition to Ind AS, the Company has followed the guidance prescribed in Ind AS 101 - First Time adoption of Indian Accounting Standard, with April 1, 2015 as the transition date. The transition to Ind AS has resulted in changes in the presentation of the financial statements, disclosures in the notes thereto and accounting policies and principles. The accounting policies set out in Note A have been applied in preparing the standalone financial statements for the year ended March 31, 2017 and the comparative information.

In terms of our report of even date attached

**For Valia & Timbadia**  
*Chartered Accountants*

**For and on behalf of the Board**

**Hiten C Timbadia**  
Partner

Date: 10th of may 2017

Place: Mumbai, India

**Prashant Savla**  
*Director*

Date: 8th of may 2017

Place: Hoofddorp, The Netherlands